Status:

COMPLETED

Investigation of Genetic Determinants of Capecitabine Toxicity

Lead Sponsor:

University of Chicago

Collaborating Sponsors:

Translational Breast Cancer Research Consortium

National Institutes of Health (NIH)

Conditions:

Breast Cancer

Eligibility:

FEMALE

18+ years

Brief Summary

The purpose of this study is to identify possible genetic polymorphisms that contribute to specific toxicities associated with capecitabine (hand-foot syndrome, diarrhea, and neutropenia). Additional...

Eligibility Criteria

Inclusion

  • women with breast cancer in whom single agent capecitabine therapy is being considered
  • aged 18 years and older

Exclusion

  • patients who have previously received capecitabine are excluded
  • patients cannot be receiving capecitabine in combination with another cancer chemotherapy; concurrent use of trastuzumab is not permitted; concurrent use of zoledronic acid is allowed
  • serum albumin less than 3.0 g/dL within the last 30 days
  • creatinine clearance (CrCL) or glomerular filtration rate (GFR) less than 60 mL/min \[/body surface area (BSA)\] (within the last 30 days)
  • inability to understand and give informed consent to participate
  • patients with a history of inflammatory bowel disease requiring therapy or patients with chronic diarrhea syndromes or paralytic ileus
  • patients with prior or concurrent pelvic irradiation
  • patients who use an ostomy for fecal excretion
  • there is no limit on the number of prior chemotherapies; the decision to use capecitabine is determined solely by the treating physician

Key Trial Info

Start Date :

November 23 2009

Trial Type :

OBSERVATIONAL

Allocation :

ACTUAL

End Date :

June 21 2021

Estimated Enrollment :

240 Patients enrolled

Trial Details

Trial ID

NCT00977119

Start Date

November 23 2009

End Date

June 21 2021

Last Update

July 31 2024

Active Locations (13)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 4 (13 locations)

1

University of Alabama - Birmingham

Birmingham, Alabama, United States, 35294

2

Georgetown University

Washington D.C., District of Columbia, United States, 20007

3

University of Chicago

Chicago, Illinois, United States, 60637

4

NorthShore University HealthSystem

Evanston, Illinois, United States, 60201

Investigation of Genetic Determinants of Capecitabine Toxicity | DecenTrialz